OB receptor cloned by Millennium and partner Hoffmann-La Roche

15 January 1996

Scientists from Millennium Pharmaceuticals and partner Hoffmann-La Roche have now cloned the human and mouse genes for the OB (leptin) protein receptor (OB-R). Previous experiments in mice and rats led to the belief that it was deficiencies in the OB protein itself that were the cause of many cases of obesity. However, initial human studies have demonstrated that most obese people are not deficient in leptin, but in fact have elevated levels of the hormone, leading to the hypothesis that it is deficiencies or faults in the OB receptor that are the major factor behind genetically-determined obesity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight